| Literature DB >> 18647386 |
Malene Herbsleb1, Karin Birkenkamp-Demtroder, Thomas Thykjaer, Carsten Wiuf, Anne-Mette K Hein, Torben F Orntoft, Lars Dyrskjøt.
Abstract
BACKGROUND: Mechanisms underlying the malignant development in bladder cancer are still not well understood. Lipolysis stimulated lipoprotein receptor (LSR) has previously been found to be upregulated by P53. Furthermore, we have previously found LSR to be differentially expressed in bladder cancer. Here we investigated the role of LSR in bladder cancer.Entities:
Year: 2008 PMID: 18647386 PMCID: PMC2492871 DOI: 10.1186/1755-8794-1-31
Source DB: PubMed Journal: BMC Med Genomics ISSN: 1755-8794 Impact factor: 3.063
Figure 1Transient overexpression of truncated LSR isoforms 1 (v1) and 3 (v3) in COS7 cells. Cell extracts were western blotted and identified by staining with polyclonal rabbit antibody. Lane 1; Mol. weight markers,; lane 2, LSR isoform 1; lane 3, LSR isoform 3.
Figure 2Immunohistochemical analysis of LSR expression in normal urothelium and bladder cancer samples. The protein was located in the cytoplasm in >50% of the cancer cells. Original magnification, ×20 (all except C), ×10 (C). A: Normal bladder urothelium (21859-99); medium LSR expression. B: Negative control stain without primary antibody of T3 grade 3 tumor (6268-96). C-D: Ta grade 2 bladder tumor (4232-97); median LSR expression. E: T1 grade 2 bladder tumor (6018-98); weak LSR expression. F: T1 grade 3 bladder tumor (5248-02); medium LSR expression. G: T3 grade 3 bladder tumor (6268-96); weak LSR expression. H: T2 grade 3 bladder tumor (1719-00); weak, overall LSR expression in cytoplasm and nucleus.
Figure 3Transient transfection of SW780 bladder cancer cells with a non-targeting siRNA (Mock), two different siRNAs against LSR (LSR1, LSR2), one siRNA against TP53 (TP53) and siRNA against LSR and TP53 in combination (LSR1+TP53). Transfected cells were harvested 18 h (one sample per siRNA constructs), 48 h (4 samples per construct) or 72 h (one sample split in two technical replicates for further analysis) after transfection and gene expression was measured using microarray analysis (HG-U133 Plus 2 arrays, GeneChip, Affymetrix). The figure shows normalized mean expression of LSR (first graph column) and TP53 (second graph column). Error bars indicate +/- one standard deviation.
Consistently differentially expressed genes at all measurements after LSR knock down by both LSR siRNAs (log2 scale).
| Location | Gene | LSR1 | LSR2 | |||||
| 18 h | 48 h | 72 h | 18 h | 48 h | 72 h | |||
| Cytoplasm | A kinase (PRKA) anchor protein (gravin) 12 | 1.2 | 1.8 | 1.9 | 1.1 | 2.1 | 2.1 | |
| Extracell. Space | follistatin | 1.8 | 3.2 | 2.8 | 1.9 | 3.9 | 3.6 | |
| amyloid beta (A4) precursor-like protein 2 | 1.3 | 1.6 | 1.1 | 1.3 | 1.6 | 1.2 | ||
| interleukin 1, alpha | 1.3 | 2.0 | 1.7 | 1.4 | 2.1 | 2.2 | ||
| cysteine-rich, angiogenic inducer, 61 | 1.1 | 2.6 | 2.2 | 1.0 | 2.3 | 2.6 | ||
| endothelin 1 | 1.2 | 3.1 | 1.8 | 1.2 | 2.7 | 2.6 | ||
| GLI pathogenesis-related 1 (glioma) | 1.4 | 2.2 | 2.6 | 1.7 | 2.8 | 2.8 | ||
| parathyroid hormone-like hormone | 1.5 | 3.3 | 3.8 | 1.0 | 3.0 | 3.2 | ||
| Nucleus | early growth response 1 | 2.0 | 3.7 | 2.5 | 2.9 | 1.6 | 3.5 | |
| myocardin | 1.1 | 1.9 | 2.1 | 1.1 | 1.5 | 1.8 | ||
| Plasma Membrane | tetraspanin 8 | -1.1 | -1.9 | -2.5 | -1.9 | -3.1 | -3.0 | |
| mal, T-cell differentiation protein-like | 1.7 | 1.3 | 1.1 | 1.4 | 1.5 | 1.3 | ||
| nexilin (F actin binding protein) | 1.4 | 1.5 | 1.3 | 1.4 | 1.7 | 1.4 | ||
| lipolysis stimulated lipoprotein receptor | -3.6 | -2.8 | -2.4 | -2.6 | -1.6 | -1.3 | ||
| Unknown | TMCO1 | transmembrane and coiled-coil domains 1 | 2.0 | 1.8 | 1.4 | 1.9 | 1.7 | 1.3 |
| TRIM31 | tripartite motif-containing 31 | -1.3 | -2.0 | -1.5 | -1.2 | -1.9 | -1.7 | |
Genes in bold are known by the Ingenuity Pathway Knowledge Base. Figures indicate log2 fold change at various time points.
Figure 4Networks top-ranked by Ingenuity Pathway analysis after knockdown of TP53 (A) and LSR1+TP53 (B). Coloured genes are upregulated (yellow) or downregulated (blue) more than 2-fold. "Focus genes" (bold) were defined as genes with a mean log ratio of ≥ |1| compared to mock transfected cells. The horizontal lines separate different cellular compartments.
Figure 5Networks top-ranked by Ingenuity Pathway analysis after knockdown of LSR1 (A-B). Coloured genes are upregulated (yellow) or downregulated (blue) more than 2-fold. "Focus genes" (bold) were defined as genes with a mean log ratio of ≥ |1| compared to mock transfected cells. The horizontal lines separate different cellular compartments.
Figure 6Networks top-ranked by Ingenuity Pathway analysis after knockdown of LSR2 (A-B). Coloured genes are upregulated (yellow) or downregulated (blue) more than 2-fold. "Focus genes" (bold) were defined as genes with a mean log ratio of ≥ |1| compared to mock transfected cells. The horizontal lines separate different cellular compartments.
"Global functional analysis" conducted using Ingenuity Pathway Analysis.
| 18 h | TP53 | Cell Death | cell death of tumor cell lines | 5.96E-09 |
| Organismal Survival | survival of mammalia | 9.59E-09 | ||
| Cell Death | cell death of lung cancer cell lines | 3.72E-08 | ||
| Organismal Survival | survival of mice | 9.84E-08 | ||
| Cellular Growth and Proliferation | colony formation of eukaryotic cells | 1.48E-07 | ||
| LSR1 | Cancer | proliferation of tumor cell lines | 3.78E-07 | |
| DNA Replication, Recombination, and Repair | synthesis of DNA | 4.61E-07 | ||
| Cell Death | apoptosis of cell lines | 1.67E-06 | ||
| Cancer | cell death of tumor cell lines | 1.95E-06 | ||
| Organismal Survival | survival of mammalia | 2.29E-06 | ||
| LSR2 | Cancer | growth of tumor cell lines | 2.11E-07 | |
| Cellular Growth and Proliferation | growth of cell lines | 3.14E-07 | ||
| Cancer | proliferation of tumor cell lines | 1.38E-06 | ||
| Cardiovascular System Development and Function | development of blood vessel | 1.78E-06 | ||
| Cellular Growth and Proliferation | growth of eukaryotic cells | 2.85E-06 | ||
| TP53+LSR1 | Cellular Growth and Proliferation | colony formation of eukaryotic cells | 5.07E-10 | |
| Organismal Survival | survival of mammalia | 8.79E-09 | ||
| Cellular Growth and Proliferation | colony formation of cell lines | 1.11E-08 | ||
| Cell Death | cell death of cell lines | 3.66E-08 | ||
| Cancer | colony formation of tumor cell lines | 1.11E-07 | ||
| 48 h | TP53 | Cell-To-Cell Signaling and Interaction | activation of eukaryotic cells | 1.17E-10 |
| Organismal Survival | survival of rodents | 1.74E-09 | ||
| Cellular Growth and Proliferation | proliferation of cell lines | 1.29E-08 | ||
| Cellular Growth and Proliferation | growth of central nervous system cells | 1.76E-08 | ||
| Cellular Growth and Proliferation | colony formation of cells | 3.72E-08 | ||
| LSR1 | Cellular Movement | cell movement | 3.26E-12 | |
| Cellular Movement | invasion of eukaryotic cells | 2.31E-11 | ||
| Cellular Movement | invasion of cell lines | 1.61E-09 | ||
| Cellular Movement | cell movement of cell lines | 3.84E-09 | ||
| Cellular Movement | cell movement of endothelial cells | 4.24E-09 | ||
| LSR2 | Cellular Movement | cell movement | 2.72E-15 | |
| Cellular Growth and Proliferation | growth of tumor cell lines | 4.45E-12 | ||
| Cellular Movement | cell movement of eukaryotic cells | 4.54E-12 | ||
| Cell-To-Cell Signaling and Interaction | adhesion of cells | 4.78E-12 | ||
| Cellular Movement | cell movement of cell lines | 7.54E-12 | ||
| TP53+LSR1 | Renal and Urological Disease | renal and urological disorder of rodents | 3.87E-08 | |
| Renal and Urological Disease | renal and urological disorder of rats | 1.05E-07 | ||
| Cancer | growth of tumor cell lines | 1.99E-07 | ||
| Cellular Growth and Proliferation | colony formation of eukaryotic cells | 5.94E-07 | ||
| Cellular Growth and Proliferation | colony formation of cell lines | 1.18E-06 | ||
| 72 h | TP53 | Tissue Development | development of tissue | 5.91E-08 |
| Tissue Development | angiogenesis of chorioallantoic membrane | 8.76E-08 | ||
| Renal and Urological Disease | renal and urological disorder of rodents | 1.01E-07 | ||
| Cancer | angiogenesis of tumor | 1.82E-07 | ||
| Cellular Movement | cell movement | 1.99E-07 | ||
| LSR1 | Cellular Movement | cell movement | 8.99E-11 | |
| Cellular Movement | migration of eukaryotic cells | 2.41E-09 | ||
| Cellular Movement | cell movement of eukaryotic cells | 2.46E-09 | ||
| Cellular Movement | cell movement of cell lines | 5.27E-09 | ||
| Cellular Movement | migration of tumor cell lines | 1.72E-08 | ||
| LSR2 | Cellular Movement | cell movement | 5.60E-15 | |
| Cellular Movement | cell movement of eukaryotic cells | 2.46E-13 | ||
| Cellular Movement | migration of eukaryotic cells | 7.57E-13 | ||
| Cellular Growth and Proliferation | growth of tumor cell lines | 5.66E-12 | ||
| Tissue Development | formation of tissue | 8.77E-12 | ||
| TP53+LSR1 | Cellular Movement | migration of eukaryotic cells | 4.19E-10 | |
| Cellular Movement | cell movement | 8.74E-10 | ||
| Cellular Movement | cell movement of eukaryotic cells | 1.57E-09 | ||
| Cancer | angiogenesis of tumor | 6.86E-09 | ||
| Renal and Urological Disease | renal and urological disorder of rodents | 8.15E-09 | ||
The list includes the annotation of the differentially expressed genes upon knockdown. The likelihood that the association between a set of differentially expressed genes and a given function was due to chance was calculated using the right-tailed Fisher's exact test. The biological functions or processes annotated to affected genes are listed according to their significance.
Figure 7Cell invasion assay. Cells were transfected with siRNAs (Mock, LSR1, TP53, LSR1+TP53) and were allowed to grow for 24 h or 48 h in control inserts (three samples per transfection) or in matrigel matrix inserts (three samples per transfection). The mean number of cells passing the inserts was calculated. Error bars indicate +/- one standard error. Asterisks (*) indicate transfections where the number of cells passing the membrane was significantly different from the mock transfected cells.
Figure 8Cellular movement and invasion network. A; log ratios of mean expression 48 h after knockdown with LSR1 compared to mean expression 48 h after knockdown with mock siRNA were overlaid. B; microarray data from 87 bladder tumors and 9 normal urothelium samples superimposed the cell movement network. Yellow represents up-regulated genes and blue represents down-regulated genes. Genes not fulfilling the cut-off criteria are not colored.